Hepion Pharmaceuticals (STU:3360) Total Receivables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3360 Hepion Pharmaceuticals Inc STU:3360
33 GF Score
Price €466.00
! 2 Warning Signs
View Full Analysis

What is Hepion Pharmaceuticals Total Receivables?

Hepion Pharmaceuticals STU:3360 33 Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:3360 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Hepion Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Hepion Pharmaceuticals Total Receivables Related Terms

Hepion Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Hepion Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals Total Receivables Chart

Hepion Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hepion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:3360
33GF Score
Hepion Pharmaceuticals Inc STU:3360
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hepion Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.00 Mil mean?
Hepion Pharmaceuticals (STU:3360) has a Total Receivables of €0.00 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Hepion Pharmaceuticals and its competitors.
Is Hepion Pharmaceuticals' Total Receivables too high?
Hepion Pharmaceuticals' current Total Receivables is €0.00 Mil. Overall, Hepion Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Hepion Pharmaceuticals' Total Receivables compare to AXIM and ZVSA?
Hepion Pharmaceuticals' Total Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Hepion Pharmaceuticals and its competitors. Hepion Pharmaceuticals's current Total Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (STU:3360) has a current Total Receivables of €0.00 Mil. The current Total Receivables is €0.00 Mil. Hepion Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Hepion Pharmaceuticals (STU:3360), the current Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hepion Pharmaceuticals Business Description

Other Exchanges HEPA:USA
Address 55 Madison Avenue, Suite 400- PMB 4362, Morristown, NJ, USA, 07960
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.
33GF Score

Get the complete analysis for STU:3360

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€466.00
Price